Nature Communications (Feb 2023)
G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma
- Maxine S. Y. Lam,
- Jose Antonio Reales-Calderon,
- Jin Rong Ow,
- Joey J. Y. Aw,
- Damien Tan,
- Ragavi Vijayakumar,
- Erica Ceccarello,
- Tommaso Tabaglio,
- Yan Ting Lim,
- Wang Loo Chien,
- Fritz Lai,
- Anthony Tan Tanoto,
- Qingfeng Chen,
- Radoslaw M. Sobota,
- Giulia Adriani,
- Antonio Bertoletti,
- Ernesto Guccione,
- Andrea Pavesi
Affiliations
- Maxine S. Y. Lam
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Jose Antonio Reales-Calderon
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Jin Rong Ow
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Joey J. Y. Aw
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Damien Tan
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Ragavi Vijayakumar
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Erica Ceccarello
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Tommaso Tabaglio
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Yan Ting Lim
- Functional Proteomics Laboratory, SingMass National Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR)
- Wang Loo Chien
- Functional Proteomics Laboratory, SingMass National Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR)
- Fritz Lai
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Anthony Tan Tanoto
- Duke-NUS Medical School
- Qingfeng Chen
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- Radoslaw M. Sobota
- Functional Proteomics Laboratory, SingMass National Laboratory, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR)
- Giulia Adriani
- Singapore Immunology Network, Agency for Science and Technology (A*STAR)
- Antonio Bertoletti
- Duke-NUS Medical School
- Ernesto Guccione
- Department of Oncological Sciences and Pharmacological Sciences, Center for Therapeutics Discovery, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- Andrea Pavesi
- Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR)
- DOI
- https://doi.org/10.1038/s41467-023-36160-5
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 18
Abstract
Engineered T cells are used for tumour immunotherapy but can have side effects and need multiple treatment rounds. Here during expansion of T cells from patients, the authors use an inhibitor of the epigenetic regulator G9a/GLP and show that this increases T cell cytotoxic function and tumour reduction in vitro and in vivo respectively.
